AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses

5 authors, including:

Ana Judith Perisé-Barrios
Instituto de Salud Carlos III
21 PUBLICATIONS   **123** CITATIONS

Teresa Cejalvo
Instituto de Salud Carlos III
31 PUBLICATIONS   **878** CITATIONS

Javier García-Castro
Instituto de Salud Carlos III
100 PUBLICATIONS   **4,062** CITATIONS

Some of the authors of this publication are also working on these related projects:

Project   Celyvir Program: A new strategy for treating metastatic / refractory pediatric tumors View project

Project   Immunotherapy View project

ARTICLE

AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses

Miguel Ángel Rodríguez-Milla[1] · Alvaro Morales-Molina [1] · Ana Judith Perisé-Barrios [1,2] · Teresa Cejalvo[1] · Javier García-Castro [1]

Abstract

There is increasing evidence about the use of oncolytic adenoviruses (Ads) as promising immunotherapy agents. We have previously demonstrated the clinical efficiency of mesenchymal stem cells (MSCs) infected with oncolytic Ads as an antitumoral immunotherapy (called Celyvir) in human and canine patients, using ICOVIR-5 or ICOCAV17 as human and canine oncolytic Ads, respectively. Considering the better clinical outcomes of canine patients, in this study we searched for differences in cellular responses of human and canine MSCs to Ad infection that may help understand the mechanisms leading to higher antitumor immune response. We found that infection of human and canine MSCs with ICOVIR-5 or ICOCAV17 did not activate the NF-κB pathway or the interferon regulatory factors IRF3 and IRF7. However, we observed differences in the profile of cytokines secretion, as infection of canine MSCs with ICOCAV17 resulted in lower secretion of several cytokines. Moreover, we showed that infection of human MSCs with ICOVIR-5 increased the phosphorylation of a number of proteins, including AKT and c-JUN. Finally, we demonstrated that differences in regulation of AKT and c-JUN in human and canine MSCs by ICOVIR-5 or ICOCAV17 are intrinsic to each virus. Our findings suggest that ICOCAV17 induces a more limited host response in canine MSCs, which may be related to a better clinical outcome. This result opens the possibility to develop new human oncolytic Ads with these specific properties. In addition, this improvement could be imitated by selecting specific human MSC on the basis of a limited host response after Ad infection.

Introduction

The use of oncolytic viruses is an immunotherapy treatment for cancer that uses viruses designed to infect and/or replicate specifically in tumor cells. Recently, Imlygic, an oncolytic virus based in herpex virus, received the approval from the Food and Drug Administration and European Medicines Agency to be used intratumorally in melanoma patients [1]. However, very limited efficacy has been

✉ Javier García-Castro
jgcastro@isciii.es

1 Cellular Biotechnology Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain

2 Biomedical Research Unit, Universidad Alfonso X el Sabio, 28691 Madrid, Spain

observed in clinical studies using intravenous delivery of oncolytic viruses. With the aim to target metastatic or widespread cancer we have developed a "Trojan horse" strategy using cellular vehicles to deliver oncolytic virus intravenously. In this regard, we have previously demonstrated the efficiency of mesenchymal stem cells (MSCs) infected with oncolytic adenoviruses (Ads) as an antitumoral immunotherapy that we called Celyvir. Thus, we reported an initial clinical experience of this treatment related with a program of compassionate use and a clinical trial in pediatric patients (NCT01844661) showing an excellent toxicity profile and several clinical responses, including two complete remissions [2–4]. More recently, we improved our immunotherapy in mice models [5, 6] and finally we tested these improvements in dogs with spontaneous tumors in a veterinary clinical trial [7]. Naturally occurring cancers in pet dogs and humans share many features, including histological appearance, tumor genetics, molecular targets, biological behavior, and response to conventional therapies [8]. Thus, in our veterinary trial including 27 canine patients treated with dCelyvir, we used dog MSCs (dMSCs) infected

with ICOCAV17—a canine Ad homologous to human ICOVIR-5—and we observed a clinical benefit in 74% of patients, including 14.8% showing complete remissions [7].

Although we have demonstrated the clinical efficacy of Celyvir, it is necessary to further explore its mechanism of action to improve its benefits. The basic elements of Ad intracellular trafficking have been described although differences have been noted related with variations based on Ad serotype, target cell type, and cell physiology [9]. In non-immune cells, signalling events activated by Ad infection are relatively well studied (e.g., phosphatidylinositol-3-kinase (PI3K), p38, ERK, and nuclear factor-κB (NF-κB)) and, although these cells may contribute to certain Ad innate reactions, the majority of these responses are originated from cells of the innate immune system such as macrophages and dendritic cells [10]. This associated immune response is also influenced by the virus type, cell type, and host species [11], and includes the following: activation of a systemic pro-inflammatory state, attracting cytotoxic immune cell populations to the sites of infection to eliminate virus-containing cells, and alarming neighboring uninfected cells of viral infection [12].

Several groups have observed specific effects after transduction of human cells with human and canine adenoviral vectors [13, 14]. Here we compared the effects of human MSCs (hMSCs) infected with ICOVIR-5 in signaling pathways to those of dMSCs infected with ICOCAV17. Considering the better clinical outcomes of dCelyvir, the observed differences have the potential to help understand the mechanisms leading to increase the clinical efficacy of Celyvir.

Materials and methods

Cell lines and cell culture

hMSCs were purchased from Lonza (Basel, Switzerland) and cultured either in Mesenchymal Stem Cell Growth Medium and the necessary supplements or in Dulbecco's modified Eagle's media (DMEM) supplemented with heat-inactivated 10% fetal bovine serum (FBS), 2 mM glutamine, streptomycin (100 mg/mL) and penicillin (100 U/mL) (complete DMEM). dMSCs and the DK28Cre cell line were obtained as indicated in ref. [7], and were cultured in complete DMEM. HEK293 cells were cultured in complete DMEM. All cell lines were maintained under standard conditions (5% CO_2, 37 °C) in their appropriate medium and routinely tested for mycoplasma contamination using the MycoAlert Micoplasm Detection Kit (Lonza). All culture reactives were obtained from Lonza with the exception of FBS, which was purchased from Sigma (St. Louis, MO, USA).

Adenovirus

ICOVIR-5 and ICOCAV17 have been extensively described elsewhere [15, 16], respectively. CAV2-GFP is a canine non-replicative adenoviral vector expressing green fluorescent protein (GFP) and was purchased from the Viral Vector Production Unit at Universitat Autònoma de Barcelona, Spain. All Ads were generated by the transfection of linearized plasmid into HEK293 (ICOVIR-5) or DK28Cre cells (ICOCAV17 and CAV2-GFP) and purified by CsCl gradient centrifugation.

Infection of MSCs, HEK293, and DK28Cre

Unless otherwise stated, MSCs were infected at different multiplicity of infection (MOI) in serum-free DMEM for 2 h at 37 °C, washed with phosphate-buffered saline (PBS), seeded and incubated in complete DMEM at 37 °C for the required time points. For analysis of viral production, human and canine MSCs were infected with ICOVIR-5 and ICOCAV17 for 3 days, then cells and medium were collected and the virus particles released by three repeated freeze–thaw cycles. Cell debris were removed by centrifugation at 1200 r.p.m. for 5 min and filtered through a 0.45 μm filter. Then, HEK293 cells (for amplification of ICOVIR-5) or DK28Cre cells (for amplification of ICO-CAV17) were seeded in 24-well plates and infected with the appropriate cell-free extract. Cells were examined every day for cytopathic effects (CPEs) using a Leica DM IL LED microscope (Leica Microsystems, Wetzlar, Germany). CAV2-GFP-infected cells were analyzed using the Leica TCS SP5 multispectral confocal microscope (Leica Microsystems) and representative images were obtained by maximum projection of four stacks.

Quantification of viral DNA by qPCR

ICOVIR-5 and ICOCAV17 genome copy number was quantified by Quantitative Real-Time PCR as previously described [17]. Briefly, total DNA from cell culture supernatants was isolated by the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Five microliters of DNA were used for Real-Time PCR using the primers ICO5-F: 5′-GAT TTG GCG CGT AAA AGT G-3′ and ICO5-R: 5′-CGG CCA TTT CTT CGG TAA TA-3′ for ICOVIR-5 and CAV2-F: 5′-CGT GAA GCG CCG TAG ATG C-3′ and CAV2-R: 5′-GAA CCA GGG CGG GAG ACA AGT ATT-3′ for ICOCAV17. Real-Time PCR consisting of 10 min at 95 °C and 40 cycles (95 °C, 10 s; 60 °C 10 s; 72 °C, 18 s) was performed on the LightCycler 1.5 Real-Time PCR Thermal Cycler (Roche, Basel, Switzerland), using LightCycler FastStart Essential DNA Green Master (Roche) and

analyzed with LightCycler Software 3.5 (Roche). A quantitative PCR standard curve was generated using tenfold serial dilutions of ICOVIR-5 and ICOCAV17 plasmid DNA, and the copy number present in the sample was obtained by extrapolation of the Ct value on the standard curve. Two independent experiments with different MSC donors were performed.

Luciferase assays

The activation of NF-κB pathway was determined using a luciferase-reporter system [18]. Replication incompetent lentiviral vectors were created using the pHAGE NF-κB-TA-LUC-UBC-GFP-W plasmid, a gift from Darrell Kotton (Addgene plasmid #49343). The plasmid encodes the NF-κB consensus binding sequence upstream of the minimal TA promoter of the herpes simplex virus followed by the firefly luciferase gene as well as the eGFP gene upstream of the ubiquitin-C promoter. Transduction of MSCs was performed overnight and GFP expression was assessed by flow cytometry. For luciferase-reporter assays, control and Ad-infected cells were lysed and luciferase activity was assayed with the Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Three independent experiments with different MSC donors were performed.

Western blot analysis

Total proteins were extracted with SDS sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 5 mM NaF, 20 mM β-glycerophosphate, 0.1 mM Na_3VO_4, and 1 : 100 protease inhibitor cocktail from Sigma). Then, samples were boiled and sonicated. Nuclear extracts were prepared using the Nuclear Extraction Kit (Abcam, Cambridge, UK) according to the manufacturer's instructions. Primary antibodies were mouse monoclonal anti-c-Jun (phospho S63) 1 : 1000 dilution (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), rabbit monoclonal anti-AKT1 (phospho S473) antibody, 1 : 1000 dilution (Epitomics, Burlingame, CA, USA), rabbit polyclonal anti-RelB 1 : 200 dilution (Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-IκB-α 1 : 200 dilution (Santa Cruz Biotechnology, Inc.), and mouse monoclonal anti-β-actin, 1 : 100,000 dilution (Sigma). Secondary antibodies were polyclonal goat anti-rabbit and anti-mouse immunoglobulins/horseradish peroxidase, 1 : 3000 dilution (DAKO, Carpinteria, CA, USA). Two independent experiments with different MSC donors were performed.

Cytokine and phospho-kinase array analysis

For the analysis of the cytokine pattern in both hMSCs and dMSCs after Ad infection, the Human XL Cytokine Array

kit (R&D Systems, Minneapolis, MN, USA) was used according to manufacturer's recommendation. The array consisted of 102 different human cytokine antibodies spotted in duplicate onto a nitrocellulose membrane. hMSCs and dMSCs from two different donors were first seeded on 6-well dishes at a density of 10^5 and 2×10^5 cells/well, respectively. Then, they were infected for 1.5 h, washed with PBS and incubated in serum-free DMEM for 3 or 24 h. Finally, supernatants from either control or Ad-infected samples were collected, centrifuged to eliminate dead cells and debris, and the protein pattern was analyzed using proteome profiler array kits. The phosphorylation profile in MSCs after Ad infection was analyzed using the Proteome Profiler Human Phospho-Kinase Array (R&D Systems) according to the manufacturer's instructions. This array detects phosphorylation of 43 human kinases and total amounts of 2 related proteins. Cell lysates (400 µg) from either control or Ad-infected samples were incubated with each set of nitrocellulose membranes of the Human Phospho-Kinase Array with the spotted capture antibodies. Array images were scanned and digitized, and integrated pixel density of the spots was quantified using the Fiji software. The average density of duplicated spots representing each protein was used to determine changes in expression of cytokines or phosphorylated proteins after adenoviral infection. Differentially expressed proteins were further studied with STRING software [19] to analyze the biological process and reactome pathways in which they are involved.

Statistical analysis

Data were analyzed and graphed using GraphPad Prism (GraphPad Software, San Diego. CA, USA). Statistical significance was determined using unpaired t-test: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$.

Results

Infection of MSCs with ICOVIR-5 and ICOCAV17 does not activate either NF-κB pathway or interferon regulatory factors IRF3 and IRF7

To compare the effects of ICOVIR-5 and ICOCAV17 infection of hMSCs and dMSCs, respectively, we first studied the sensitivity of both cells to each Ad. For the clinical trial of hCelyvir, ICOVIR-5 was used at a MOI of 200 plaque-forming units (PFU)/cell because that was the average MOI obtained in previous studies for the infection of hMSCs from different donors [4]. For our veterinary trial of dCelyvir [7], we used ICOCAV17 at a MOI of 1 PFU/cell based in previous results using this oncolytic Ads,

where the IC50 values infecting canine tumoral cell lines ranked 0.5–15 PFU/cell [16]. Thus, we compared hMSCs and dMSCs infected at these MOIs and observed that they were infected to an equivalent degree (Supplementary Fig. S1). First, Ad infection caused similar CPE, which started at 2 days post infection. In addition, Ad titers obtained from supernatant cultures were comparable (Fig. 1a). However, when hMSCs were infected at 1 PFU/cell no detectable CPE was observed, whereas infection of dMSCs at 200 PFU/cell caused excessive early CPE (Supplementary Fig. S1). Therefore, as our goal was to compare Ad-induced effects in MSCs in hCelyvir and dCelyvir under clinical conditions (healthy MSCs able to undergo tumor-homing during 24–48 h post infection), we performed all the experiments under the conditions previously published.

Ad infection leads to the activation of intracellular signaling cascades as a virus-induced innate response of the cells [10]. We first searched for Ad-induced differences in immune-related pathways in hMSCs and dMSCs. As NF-κB is classically activated by Ads and activates numerous early response genes, including genes encoding for inflammatory cytokines and chemokines [20], we studied its activation using a lentiviral vector expressing a luciferase-reporter gene under a NF-κB promoter. No significant differences in luciferase levels were observed at the times studied in either type of cell (Fig. 1b). Similarly, immunoblotting experiments revealed that proteins involved in the induction of the canonical (IκB-α) and non-canonical (RelB) NF-κB pathways, as well as interferon (IFN) regulatory factors IRF3 and IRF7, which activate the transcription of IFN-α or IFN-β, respectively, were constitutively expressed at similar levels in infected cells compared with the control (Fig. 1c, d). Nevertheless, we observed a slight decrease in IκB-α in hMSCs after 24 h of infection consistent with the small increase in luciferase levels shown in Fig. 1a.

Analysis of cytokines in MSCs displays different secretion profiles

Next, we investigated the profiles of cytokine secretion in MSCs in response to Ad infection using a human cytokine antibody array, as other human arrays have been successfully used in the analysis of canine samples [21]. Overall, a more complex profile was detected at 3 h post infection compared with 24 h. Thus, at 3 h, signal above background level was detected in hMSCs for all 105 cytokines implemented in the array compared with 71 in dMSCs (Fig. 2a). However, after 24 h, signal was detected only for 41 cytokines in hMSCs compared with 19 in dMSCs (Fig. 2b). When we compared ICOVIR-5-infected hMSCs to ICOCAV17-infected dMSCs, no major differences were


Fig. 1 NF-KB signaling pathway activity and IRFs phosphorylation after adenoviral infection of human and canine MSCs. All the experiments were performed using hMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) and dMSCs infected with ICOCAV17 (MOI 1 PFU/cell). **a** Culture supernatants of infected MSC were collected at various times post infection and Ad titers measured as described in Methods. Ad titers of hMSCs and dMSCs analyzed at the indicated times post infection. Graphs show mean + SD ($n = 3$) ($\log_{10}$ scale). **b** Luciferase activity of hMSCs and dMSCs transduced with the NF-KB-reporter lentiviral vector after Ad infection at the indicated times. Graphs show mean + SD fold increase ($n = 3$). **c, d** Western blottings of total or nuclear extracts (ne) from hMSCs and dMSCs were probed with the indicated antibodies. Two independent experiments with different MSC donors were performed.

found on the levels of secreted cytokines. Thus, the array included well-characterized pro-inflammatory cytokines (interleukin (IL)-1, IL-6, IL-8, IL-12, IFN-γ, IL-18, and tumor necrosis factor) whose analysis showed no significant differences between infected and control samples (Fig. 2a, b). This is consistent with the lack of activation of NF-κB

Fig. 2 Array analysis of secreted cytokines in human and canine MSCs after Ad infection. Serum-free medium from hMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) and dMSCs infected with ICO-CAV17 (MOI 1 PFU/cell) for the indicated times was collected and a secretory profile obtained using the Human XL Cytokine Array kit. The heat maps show the detected cytokines above background level in at least one cell type. All 102 cytokines present in the array were identified after 3 h of infection (**a**), whereas only 51 after 24 h (**b**). **c**, **d** Statistical analysis showing differentially expressed cytokines (infected vs. control ratios) in hMSCs (purple) and dMSCs (yellow) in response to Ad infection (T-test: $p < 0.05$) (**c**, 3 h; **d**, 24 h). Two independent experiments with different MSC donors were performed.

pathway observed above (Fig. 1b–d). Nevertheless, there were significant differences in fold change of four cytokines (ST2, TARC, THBS1, and µPAR) after Ad infection, showing a higher downregulated expression in ICOCAV17-infected dMSCs compared with ICOVIR-5-infected hMSCs (Fig. 2c, d).

AKT and JUN are differentially regulated in hMSCs and dMSCs after infection with ICOVIR-5 and ICOCAV17

To determine whether other signaling pathways were altered by Ad infection in MSCs, since Ad-induced

Fig. 3 Signaling pathways regulated by Ad infection in human and canine MSCs. a, b Heat maps showing phospho-kinase profiles in cell lysates of hMSCs and dMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) or ICOCAV17 (MOI 1 PFU/cell) for the indicated times obtained with the Human Phospho-Kinase Antibody Array. **c, d** Statistical analysis showing differentially expressed phospho-kinases in hMSCs and dMSCs in response to Ad infection at 3 (**c**) or 24 h (**d**). (T-test: $p < 0.05$). **e, f** Network presenting cytokines with increased infected/control ratios in hMSCs compared to dMSCs at 3 (**e**) and 24 h (**f**). Line thickness indicates the strength of data support between edges. Colors represent the biological process in which the cytokine is involved according to the legend.

phosphorylation of several proteins is well described [10], we utilized a human phospho-kinase array to detect changes in phosphorylation profiles of kinases and their substrates. hMSCs and dMSCs were infected with ICOVIR-5 and ICOCAV17 and phosphorylation profiles analyzed at 3 and 24 h post infection (Fig. 3a, b). Analysis of phosphorylation profiles in ICOVIR-5-infected hMSCs compared to ICOCAV17-infected dMSCs resulted in some significant changes at 3 and 24 h post infection (Fig. 3c, d) although

the differences observed were very small in most cases (especially at 3 h). However, after 24 h, ICOVIR-5 and ICOCAV17 infection of hMSCs and dMSCs resulted in strong contrasting effects on the phosphorylation levels of AKT (fold change: 33.3 in hMSCs compared with −0.3 in dMSCs) and c-JUN (fold change: 1.4 in hMSC compared with −1 in dMSCs). Similar significant results were observed for GSK-3 α/β and CREB. Considering the well-known roles of the AKT and c-JUN pathways during Ad

infection [10], we further validated the expression of both proteins in different donors using western blot analysis (Supplementary Fig. S2). Consistent with the results from the array, phosphorylation of both AKT and c-JUN in hMSCs infected with ICOVIR-5 increased at 24 h post infection. In contrast, none pathway was activated in dMSCs infected with ICOCAV17. In both cases, the observed changes were dose dependent.

STRING analysis depicted networks of interactions of the significantly higher secreted cytokines and phosphorylated proteins in infected hMSC compared to infected dMSC at 3 h (Fig. 3e) and 24 h (Fig. 3f). Gene Ontology enrichment analyses identified biological processes that are associated with positive regulation of cellular process, negative regulation of cell death, regulation of apoptosis, and regulation of autophagy.

Regulation of AKT and JUN in hMSCs and dMSCs by ICOVIR-5 or ICOCAV17 infection is intrinsic to each specific adenovirus

Considering the contrasting differences observed between human and canine Ads in AKT and c-JUN phosphorylation, we further tested whether these responses were host- or Ad-specific. We then performed host-cross infections of human and canine Ads (Fig. 4a). We found out that ICOVIR-5 was able to replicate in some degree in dMSCs, as a strong CPE was observed in HEK293 cells infected with virus released from ICOVIR-5-infected dMSCs (Fig. 4a-II). In addition, Ad titers were similar to those obtained for ICOVIR-5-infected hMSCs (Fig. 4b). By contrast, ICOCAV17 infection of hMSCs was very inefficient as the CPE caused to DK28Cre cells infected with virus released from ICOCAV17-infected hMSCs was very weak (Fig. 4a-IV) and Ad titers were very low (Fig. 4b). Indeed, when hMSCs were infected with CAV2-GFP, a non-replicative canine Ad vector, no fluorescence was observed, whereas infection of dMSCs resulted in strong GFP signal (Fig. 4c). Finally, infection of dMSCs with human ICOVIR-5 resulted in a strong phosphorylation of AKT and c-JUN similar to ICOVIR-5-infected hMSCs but no activation of AKT and c-JUN was observed when hMSCs were infected with ICOCAV17 (Fig. 4d).

Discussion

The aim of this study was to identify specific responses induced by ICOVIR-5 and ICOCAV17, and human and canine oncolytic Ads, respectively, upon infection of MSCs that may be related to the better clinical outcome of dCelyvir. Other studies using human cells infected by human and canine Ads have identified specific responses of each

virus [13, 14]. By contrast, we searched for differences between ICOVIR-5-infected hMSCs and ICOCAV17-infected dMSC. Our data suggest that NF-κB pathway, IFNs, and pro-inflammatory cytokine secretion are not the primary sensors of Ad infection in hMSCs and dMSCs. Similarly, it has been shown that transduction of rat MSCs with human adenoviral vectors has no major influence on the expression profile of immunologically relevant parameters [22]. Although we observed distinct cytokine secretion profiles, part of the differences observed in our non-infected samples may be due to lack of homology between human and canine cytokines. Nevertheless, we demonstrated that hMSCs and dMSCs displayed Ad-induced changes in the secretion of ST2, TARC, THBS1, and µPAR. These differences found were mostly due to decreased secretion in dCelyvir, not by higher secretion in hCelyvir (with the exception of TARC). Thus, the decrease of these cytokines, together with the overall reduction of cytokine secretion after 24 h in dMSCs indicates that dCelyvir presents a lower profile of cytokine expression.

Interestingly, when we compared the activation of other important signaling molecules, a number of differentially phosphorylated targets were identified. It is known that many viruses modulate the signaling pathways of the host cell to escape activation of key innate immune mechanisms and establish a productive infection [23]. Thus, some viruses activate PI3K–AKT signaling for latent infection and others for short-term cellular survival during the initial stages of acute infection, when virus replication and protein synthesis are taking place [24]. Accordingly, our findings that ICOVIR-5 induces a strong phosphorylation of AKT and c-JUN in hMSCs after 24 h of infection, whereas ICOCAV17 does not activate these pathways in dMSCs, indicate that ICOCAV17 induces a more limited host response than ICOVIR-5. The fact that ICOVIR-5, a human Ad, can also activate AKT and c-JUN in canine MSCs demonstrates that these cells can activate these pathways in response to other Ads. These data indicate that the impaired cellular signaling after infection is intrinsic to ICOCAV17. Together with the observed decreased cytokine secretion, the results suggest that ICOCAV17 somehow avoids host cell signaling in dMSCs.

Activation of PI3K/AKT and AP-1 signaling pathways by Ads is well established, and the roles of these pathways in cell survival and apoptosis are known. Remarkably, Ad activation of the PI3K/AKT pathway maintains host cell viability during viral replication and therefore benefits the virus rather than the host [25]. Moreover, activation of JUN kinases and AKT has been proposed to be required for Ad-mediated autophagy necessary for their lytic cycle, using Δ24RGD, an Ad very similar to ICOVIR-5 [26]. Binding of the Ad penton base RGD motif to α_v integrins induces phosphorylation of several signaling proteins, including

Fig. 4 Differences in replication and signaling between ICOVIR-5 and ICOCAV17 depending on cell host. a Scheme showing the experimental design of host-crossed infections. Bright field micrographs (100X total magnification) showing the cytopathic effect observed in HEK293 or DK28CRE cells with cell-free extracts from hMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) (I), dMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) (II), dMSCs infected with ICOCAV17 (MOI 1 PFU/cell) (III) or hMSCs infected with ICOCAV17 (MOI 1 PFU/cell) (IV). In all cases, cell-free extracts were obtained at 72 h post-infection. Uninfected cells were used as controls. **b** Culture supernatants of hMSCs and dMSCs infected with ICOVIR-5 (MOI 200 PFU/cell) or ICOCAV17 (MOI 1 PFU/cell) were collected at various times post-infection and Ad titers measured as described in Methods. Graphs show mean + SD ($n = 3$) ($\log_{10}$ scale). **c** Western blottings of dMSCs and hMSCs infected for 24 h with ICOVIR-5 (MOI 200 PFU/cell) or ICOCAV17 (MOI 1 PFU/cell) were probed with the indicated antibodies. **d** Confocal analysis of dMSCs and hMSCs infected with CAV2-GFP (MOI 10 PFU/cell). Positive signal was detected in dMSCs, whereas fluorescence was missing in hMSCs.

FAK and PI3K [27], but canine Ads do not contain a RGD motif in their penton base, using the Coxsackie and Ad receptor (CAR) or other primary receptors to bind the cells [28]. This absence of RGD(penton base)-integrin interactions would be the cause of this different intracellular activation after ICOVIR-5 and ICOCAV17 infection.

However, both Ads include artificial RGD motifs in the HI loops of their fibers [15, 16]. That positioning of the RGD motif within the knob of Ad fiber protein should make this ligand available for efficient interaction with integrins on the cell membrane [29]. Nevertheless, so far is not known whether this RGD(Knob)-integrin interaction would generate the same or different intracellular signaling events comparing with RGD(penton base) motifs.

Moreover, other authors have also reported altered responses between human and canine Ads after infection of human cells. Thus, transduction of dendritic cells has shown that the canine adenoviral CAV2 vectors, in contrast to human adenoviral serotype-5 vectors, provoked minimal upregulation of major histocompatibility complex class I/II and costimulatory molecules (CD40, CD80, and CD86), and induced negligible morphological changes indicative of dendritic cell maturation [13]. Similarly, transduction of neurons with human and canine adenoviral vectors resulted in distinct transcriptome profiles [14]. By the other hand, the CAV2 capsid is approximately 10-fold-less negatively charged than human Ad5 [28]. It is possible that the more neutral net charge of the CAV2 capsid induce a different attachment to MSC, with a different signaling induction after infection. In addition, a more flexible CAV2-CAR interaction compared to human Ad5-CAR has been suggested [30], which would also have a role in cellular attachment, internalization and intracellular signaling.

We propose the hypothesis that the absence of activation of AKT and c-JUN pathways by ICOCAV17 may result in a more 'silent' infection that improves the efficacy of dCelyvir. Thus, in ICOVIR-5-infected hMSCs, cellular processes induced by AKT/c-JUN phosphorylation may prevent the activation of the same mechanisms induced in dCelyvir. It is tempting to speculate that part of these results may be due to functional differences in viral proteins. Besides, clinical responses in human patients were achieved when hMSCs presented a lower pro-inflammatory profile after Ad infection, indicating some degree of natural Ad-sensitivity between patients [3]. Our results open the possibility to develop new oncolytic Ads with these specific properties. In addition, this mechanism of action could be imitated in clinical hCelyvir by selecting specific human allogeneic MSCs on the basis of their limited host response after Ad infection.

Compliance with ethical standards

References

1. Garnock-Jones K. Talimogene Laherparepvec: a review in unresectable metastatic melanoma. BioDrugs. 2016;30:461–8.
2. García-Castro J, Alemany R, Cascalló M, Martínez-Quintanilla J, Arriero MM, Lassaletta A, et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010;17:476–83.
3. Melen GJ, Franco-Luzon L, Ruano D, Gonzalez-Murillo A, Alfranca A, Casco F, et al. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 2016;371:161–70.
4. Ruano D, Lopez-Martin JA, Moreno L, Lassaletta A, Bautista F, Andion M, et al. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors. Mol Ther. 2020;28:1033–42.
5. Rincón E, Cejalvo T, Kanojia D, Alfranca A, Rodríguez-Milla MA, Gil Hoyos RA, et al. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. 2017;8:45415–31.
6. Morales-Molina A, Gambera S, Cejalvo T, Moreno R, Rodriguez-Milla MA, Perise-Barrios AJ, et al. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. Cancer Immunol Immunother. 2018;67:1589–602.
7. Cejalvo T, Perisé-Barrios AJ, Portillo Id, Laborda E, Rodriguez-Milla M, Cubillo I, et al. Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy. Cancer Res. 2018;78:4891–901.
8. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147–56.
9. Leopold PC. RG. Intracellular trafficking of adenovirus: many means to many ends. Adv Drug Deliv Rev. 2007;59:810–21.
10. Fejer G, Freudenberg M, Greber U, Gyory I. Adenovirus-triggered innate signalling pathways. Eur Jl Microbiol Immunol. 2011;1:279–88.
11. Flatt J, Butcher S. Adenovirus flow in host cell networks. Open Biol. 2019;9:190012.
12. Atasheva S, Shayakhmetov D. Adenovirus sensing by the immune system. Curr Opin Virol. 2016;21:109–13.
13. Perreau M, Mennechet F, Serratrice N, Glasgow J, Curiel D, Wodrich H, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol. 2007;81:3272–84.
14. Piersanti S, Astrologo L, Licursi V, Costa R, Roncaglia E, Gennetier A, et al. Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles. PLoS ONE. 2013;8:e69808.
15. Cascallo M, Alonso M, Rojas J, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther. 2007;15:1607–15.

16. Laborda E, Puig-Saus C, Rodriguez-Garcia A, Moreno R, Cascallo M, Pastor J, et al. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Mol Ther. 2014;22:986–98.

17. Segura MM, Monfar M, Puig M, Mennechet F, Ibanes S, Chillon M. A real-time PCR assay for quantification of canine adenoviral vectors. J Virol Methods. 2010;163:129–36.

18. Wilson A, Kwok L, Porter E, Payne J, McElroy G, Ohle S, et al. Lentiviral delivery of RNAi for in vivo lineage-specific modulation of gene expression in mouse lung macrophages. Mol Ther. 2013;21:825–33.

19. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47 (D1):D607–d13.

20. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, et al. Coagulation factor X activates innate immunity to human species C adenovirus. Science. 2012;9:795–8.

21. McCleese J, Bear M, Kulp S, Mazcko C, Khanna C, London C. Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol. 2013;11:124–39.

22. Treacy O, Ryan A, Heinzl T, O'Flynn L, Cregg M, Wilk M, et al. Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. PLoS ONE. 2012;7:e42662.

23. Bowick G, Fennewald S, Scott E, Zhang L, Elsom B, Aronson J, et al. Identification of differentially activated cell-signaling networks associated with Pichinde virus pathogenesis by using systems kinomics. J Virol. 2007;81:1923–33.

24. Cooray S. The pivotal role of phosphatidylinositol 3-kinase–Akt signal transduction in virus survival. J Gen Viro. 2004;85:1065–76.

25. Rajala MS, Rajala RV, Astley RA, Butt AL, Chodosh J. Corneal cell survival in adenovirus type 19 infection requires phosphoinositide 3-kinase/Akt activation. J Virol. 2005;79:12332–41.

26. Klein S, Piya S, Lu Z, Xia Y, Alonso M, White E, et al. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene. 2015;34:5295–301.

27. Li E, Stupack D, Klemke R, Cheresh DA, Nemerow GR. Adenovirus endocytosis via α v integrins requires phosphoinositide-3-OH kinase. J Virol. 1998;72:2055–61.

28. Soudais C, Boutin S, Hong Sea. Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol. 2000;74:10639–49.

29. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706–13.

30. Seiradake E, Lortat-Jacob H, Billet O, Kremer EJ, Cusack S. Structural and mutational analysis of human Ad37 and canine adenovirus 2 fiber heads in complex with the D1 domain of coxsackie and adenovirus receptor. J Biol Chem. 2006; 281:33704–16.